The Pharmaceutical Market: Denmark

Publisher Name :
Date: 25-Apr-2013
No. of pages:

OVERVIEW OF THE PHARMACEUTICAL MARKET IN DENMARK

The macroenvironment for the Danish pharmaceutical industry is improving. The centre-left coalition, of the Social Democratic Party, the Socialist People’s Party and the Social Liberal Party, took office in October 2011. Denmark suffered a deep recession and economic recovery is stalling with negative GDP growth projected for 2012. Denmark has an ageing population, and the Economist Intelligence Unit projects that the population aged 65 and over will constitute more than one-fifth of the total population by 2016. As a result, healthcare is increasingly focused on preventative care and there will be a continuing demand for new therapies so that patients can be treated more effectively.

The increasing pharmaceutical expenditure in Denmark has led to price freezes and caps in recent years. A price ceiling, which has fixed pharmaceutical prices at the level they were five years ago, was extended to remain in place until the end of 2011. This extension is a sign of the government’s determination to keep the price of pharmaceuticals down, and so this form of price restriction is likely to continue beyond 2011. However, despite the positive results from cost-containment measures, efforts to reduce the cost of pharmaceuticals have proved unsuccessful. The savings made have been more than counterbalanced by the wider use of new and expensive pharmaceuticals, which are required to ensure the most effective treatment. This is especially true in areas such as hypertension, high cholesterol and so on, where many new therapies have become available recently.

Denmark has strong domestic production, but many producers focus on the export market. Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. In August 2011, Novo Nordisk announced it is planning to build two new office buildings in Bagsværd. Previously, in June 2011, the company announced it is to invest in a new plant in Kalundborg, for the production of biopharmaceuticals.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Denmark

Table Of Contents
N/A

  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Bulgaria Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: The Ministry of Health's plan to increase MAH fees, coupled with price cuts for generic drugs and freezes on OTC medicine prices indicate that the Bulgarian pharmaceutical market will not see meaningful growth in 2014. However, we expect a pickup in demand for innovative drugs to reinvigorate interest in the country, although it will continue to present a relatively small opportunity for drugmakers in the region. Headline Expenditure Projections ? Pharmaceuticals: BGN2.32bn (USD1.58bn)......
  • Taiwan Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 136
    BMI View: BMI believes that cost-containment policies will not place significant pressure on healthcare expenditure in Taiwan. This is because the majority of spending in the medical services sector goes towards salaries for doctors and nurses, which are difficult to cut back on without arousing political opposition. Meanwhile, the needs of the ageing population mean that demand is increasing for innovative pharmaceuticals and medical devices, which will sustain higher health expenditure. Taiwan......
  • Austria Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 65
    BMI View: Austria's economy is set to grow at a faster clip in the second half of 2014 and domestic consumer demand is poised to strengthen in this period. We have revised the healthcare and pharmaceutical market forecast slightly upwards to reflect this. The EUR-USD exchange rate continues to provide investment opportunities for overseas investors. In the medium term, Austria's pharmaceutical and healthcare spending will post weak growth as the government caps growth in public healthcare expend......
  • Sudan Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 56
    BMI View: Overall pharmaceutical sales in Sudan and South Sudan are to see double-digit growth, albeit from a low base. In addition, we highlight that high inflation, volatile currency exchange rates and civil unrests are some of the key risks that will continue to limit pharmaceutical growth potential in Sudan and South Sudan. Headline Expenditure Projections ? Pharmaceuticals: SDG2.60bn (USD560mn) in 2013 to SDG3.29bn (USD540mn) in 2014; +26.4% in local currency terms and -3.1% in US dollar te......
  • Slovenia Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 95
    ? BMI View: Political instability caused by the collapse of the coalition government and the resignation by the prime minister has increased the risk of a slowdown in GDP growth and a likely loss of momentum in structural reforms. Therefore, the burden of healthcare cuts, under pressure from the EU and IMF, will fall on the pharmaceutical industry. Although public healthcare funding had managed to eliminate its deficit in 2013, undertaking healthcare reform has proved to be politically difficult......
  • Singapore Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 131
    BMI View: The considerable increase in the government's healthcare expenditure highlights Singapore's commitment to provide better, more affordable healthcare services for its population, particularly the elderly. The government's aim to further increase its expenditure to 40% of the total health expenditure will bring about commercial benefits for healthcare players and pharmaceutical manufacturers, as it will potentially increase patient's access to healthcare. We highlight a need for the coun......
  • Romania Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 114
    BMI View: Our above-consensus outlook for economic growth in Romania has borne out, with positive implications for the pharmaceutical sector. With wages set to rise and consumer spending continuing to grow at a rapid clip, consumer non-discretionary spending is set to tick higher. We see over-the-counter medicines and potentially generic medicines benefitting from an improving consumer picture. Over the longer term, Romania's competitive labour costs are set to catalyse an influx of manufacturin......
  • Cote d’Ivoire Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 59
    BMI View: Despite our more positive outlook for economic and pharmaceutical growth in Cote d'Ivoire over the long term, the country remains one of the least attractive to multinationals looking to launch innovative products in Africa. This is due to risks in its pharmaceutical environment, including poor patent respect, lack of policy enforcement and approvals expediency and a weak business setting. The healthcare market remains underdeveloped, while the burden of communicable diseases is consid......
  • Puerto Rico Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 99
    BMI View: The pharmaceutical manufacturing industry will continue to be an economic mainstay for Puerto Rico. However, the country is gradually losing attractiveness as a global pharmaceutical production hub, despite the diversification to the generic and biologic drug production. Headline Expenditure Projections ? Pharmaceuticals: USD3.02bn in 2013 to USD3.02bn in 2014; +0.2% in local currency terms. Forecast is below the previous quarter's projection due to new historical numbers. ? Healthcare......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs